Raising Awareness about Blood Cancers: A Diverse and Complex Group of Diseases

Blood Cancers: A Diverse and Complex Group of Diseases

With Progress Comes New Challenges

Despite the challenges brought on by the pandemic, much progress has been made over the past two decades to understand the disease biology and treatment of many blood cancers, like multiple myeloma, that has significantly altered survival rates in patients. With a range of new treatment options and advanced technologies that have enabled earlier diagnoses, people with many forms of these diseases are living longer and better than ever before.  

Still, there's more to do to improve survival and extend periods of remission. Through our broad clinical development program and diverse portfolio, we’re evaluating a range of potential new therapies and combinations for blood cancers that remain hard-to-treat, to ensure we’re leaving no patient behind.  

Supporting a Growing Patient Community: The Road Ahead

There are also many new considerations for patients in today’s environment, who may be facing issues with access to treatment, inadequate blood supply or are experiencing added stress and isolation. That’s why we partner with many advocacy organizations that provide resources and harness the invaluable connection of the virtual patient community.  

We’re optimistic that the lessons learned during this time will yield more effective and accessible approaches to clinical trial design, helping us reach more patients and continuing to accelerate the development of new options that are urgently needed.   

As we reflect on progress made and our path forward during Blood Cancer Awareness Month, one thing is certain: we can’t do this alone. We’re continuing to partner with a broad network of researchers, healthcare professionals and advocacy groups to develop more personalized and effective treatment options, resources and support until we’ve identified an approach for every patient.